Chong Kun Dang Pharmaceutical Corp. (KRX: 185750)

Chong Kun Dang Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	1,666,522	1,669,404	1,488,345	1,343,559	1,303,006	1,079,338
Other Revenue	0	-	-	-	-	0
Revenue	1,666,522	1,669,404	1,488,345	1,343,559	1,303,006	1,079,338
Revenue Growth (YoY)	8.07%	12.17%	10.78%	3.11%	20.72%	12.88%
Cost of Revenue	1,010,926	1,007,203	945,705	847,741	813,866	675,059
Gross Profit	655,597	662,202	542,639	495,818	489,140	404,279
Selling, General & Admin	263,430	256,595	237,936	220,982	202,292	215,851
Research & Development	135,628	140,235	176,325	163,277	146,664	98,624
Other Operating Expenses	12,203	11,694	11,387	12,206	10,184	10,060
Operating Expenses	418,817	415,602	432,733	401,060	365,204	329,703
Operating Income	236,780	246,599	109,906	94,759	123,936	74,576
Interest Expense	-8,797	-9,271	-6,847	-4,030	-3,871	-3,151
Interest & Investment Income	10,360	6,028	2,333	759.37	1,387	898.65
Earnings From Equity Investments	612.85	798.36	-460.38	-603.47	-	-
Currency Exchange Gain (Loss)	285.51	-2,356	-2,524	-183.41	-569.56	-507.19
Other Non Operating Income (Expenses)	-1,749	-1,777	838.33	-10,128	371.38	1,448
EBT Excluding Unusual Items	237,491	240,021	103,246	80,573	121,253	73,264
Gain (Loss) on Sale of Investments	947.63	1,465	-2,223	-98.87	517.38	-612.69
Gain (Loss) on Sale of Assets	-25.64	111.88	54.05	119.34	68.18	91.44
Asset Writedown	-883.14	-	-3,912	-	-	-922
Pretax Income	237,530	241,598	97,165	80,594	121,839	71,821
Income Tax Expense	21,469	27,996	17,187	38,237	31,434	18,846
Earnings From Continuing Operations	216,061	213,602	79,978	42,356	90,405	52,975
Minority Interest in Earnings	-3,273	-1,081	975.58	363.91	1,228	906.36
Net Income	212,788	212,521	80,953	42,720	91,633	53,882
Net Income to Common	212,788	212,521	80,953	42,720	91,633	53,882
Net Income Growth	78.75%	162.52%	89.50%	-53.38%	70.06%	27.08%
Shares Outstanding (Basic)	13	13	13	13	13	13
Shares Outstanding (Diluted)	13	13	13	13	13	13
Shares Change (YoY)	-0.51%	-0.76%	-1.77%	-0.73%	-0.06%	-0.04%
EPS (Basic)	16762.86	16704.14	6314.33	3273.25	6969.42	4095.66
EPS (Diluted)	16762.86	16704.14	6314.33	3273.25	6969.42	4095.66
EPS Growth	79.66%	164.54%	92.91%	-53.03%	70.17%	27.14%
Free Cash Flow	219,644	276,942	22,836	-35,339	71,684	55,454
Free Cash Flow Per Share	17302.98	21767.61	1781.20	-2707.69	5452.18	4215.17
Dividend Per Share	1047.619	1047.619	-	-	-	-
Gross Margin	39.34%	39.67%	36.46%	36.90%	37.54%	37.46%
Operating Margin	14.21%	14.77%	7.38%	7.05%	9.51%	6.91%
Profit Margin	12.77%	12.73%	5.44%	3.18%	7.03%	4.99%
Free Cash Flow Margin	13.18%	16.59%	1.53%	-2.63%	5.50%	5.14%
EBITDA	274,307	283,629	143,504	122,241	147,721	97,628
EBITDA Margin	16.46%	16.99%	9.64%	9.10%	11.34%	9.05%
D&A For EBITDA	37,527	37,030	33,598	27,482	23,786	23,052
EBIT	236,780	246,599	109,906	94,759	123,936	74,576
EBIT Margin	14.21%	14.77%	7.38%	7.05%	9.51%	6.91%
Effective Tax Rate	9.04%	11.59%	17.69%	47.44%	25.80%	26.24%
Advertising Expenses	-	69,707	60,364	51,329	45,629	52,504

Source: S&P Capital IQ. Standard template. Financial Sources.